Summary:
- This article announces that Rezurock, a medication developed by Sanofi, has been approved for use in the European Union to treat chronic graft-versus-host disease (cGVHD).
- cGVHD is a serious complication that can occur after a stem cell or bone marrow transplant, where the donor's immune cells attack the recipient's healthy cells.
- Rezurock is a new treatment option that can help manage the symptoms of cGVHD and improve the quality of life for patients who are dealing with this condition.